

NEW

QUATTRO®

A FORMULA
AS PURE
AS YOUR CARE

Inspired by you to give them the best



Ecto-endoparasitario de Múltiple
Acción y dosis baja
Acción adulticida, ovicida y
larvicida
Multi-action ecto-endoparasiticide
with low dosage
Adulticidal, ovicidal and larvicidal
activity

**35 Días de
protección**
35 Days of protection

Actúa a partir
de **90 minutos**
Starts killing
within 90 minutes

BENEFITS



Molecular efficiency via active enantiomers

Suralan® Quattro® utilizes chiral technology to administer only the isomers with biological activity (S-Sarolaner and R-Praziquantel), which allows for the reduction of the systemic metabolic load by eliminating inactive components.



Therapeutic precision and lower toxicity

By excluding unnecessary isomers, the potential for adverse effects is minimized and patient safety is optimized, raising the pharmacological standard of the dose.



Up to 35 days of sustained protection

Its molecular purity guarantees a sustained efficacy that extends protection beyond the calendar month, facilitating owner compliance and treatment continuity.



Palatability via isomeric selection

The exclusive use of Arpraziquantel (R-Praziquantel) eliminates the characteristic bitter taste of the inactive isomer, achieving high palatability.



Precise coverage for every life stage and size

Suralan® Quattro® features 6 presentations that allow for accurate dosing starting from 8 weeks of age and 1.25 kg of weight, up to dogs of 60 kg, providing protection adapted to each patient.




Thanks to the wide safety margin of moxidectin within this formulation, Suralan® Quattro® has demonstrated excellent tolerability. However, in sensitive herding breeds known to carry the MDRI (-/-) mutation, its administration should be clinically evaluated and supervised by a veterinarian, strictly adhering to the recommended dosage.



PROTECTION FOR 35 DAYS HIGH-EFFICACY

Low-dose antiparasitic with superior absorption and fast action

WHEN CARE IS PURE THEY CAN FEEL IT



Suralan® Quattro® is more than an innovation; it is a breakthrough in veterinary pharmacology aimed at maximizing the patient's safety profile. The use of our exclusive pure chiral technology, based on the administration of active enantiomers, translates into a lower metabolic load and greater therapeutic precision.

Suralan® Quattro® combines comprehensive, broad-spectrum protection with a highly palatable formulation, optimizing compliance from the very first dose. Because when care is pure, they can feel it.

The chemical purity of S-Sarolaner and Arpraziquantel (R-Praziquantel) guarantees superior protection by delivering only the biologically active components of the formulation.

SURALAN® QUATTRO® FOUR MOLECULES WITH **ADVANCED** TECHNOLOGY

Suralan® Quattro® combines the power of four active ingredients in a cutting-edge formulation. Thanks to our exclusive Averstab 640® technology (stabilized Moxidectin) and the Bitter off® palatability system, we guarantee superior efficacy and immediate acceptance.

- 1 S-Sarolaner (Pure Enantiomer):**
An isoxazoline with superior potency against fleas and ticks. The fluorine radical in its structure enhances its acaricidal activity.
- 2 Arpraziquantel (R-Praziquantel):**
A pure cestocide where almost all the biological activity resides. It eliminates the bitter taste of the inactive (S) isomer.
- 3 Moxidectin:**
A lipophilic macrocyclic lactone with high affinity for adipose tissue, ideal for the prevention of dirofilariasis.
- 4 Pyrantel embonato:**
A nicotinic agonist with low systemic absorption, guaranteeing high concentration and action within the intestinal lumen.



suralan®

QUATTRO®



80 minutes²
Average Onset
of Action



**35 days of
Protection**

Its pharmacological design is based on **pure enantiomeric technology**, combining four complementary active ingredients to deliver comprehensive protection.

Suralan® Quattro® is administered orally, as a single tablet tailored to the patient's weight range. The dosage is meticulously engineered to achieve the minimum recommended therapeutic doses: 2 mg/kg of sarolaner, 0.024 mg/kg (24 µg/kg) of moxidectin, 5 mg/kg of pyrantel (as embonate), and 2.5 mg/kg of arpraziquantel*.

CONCENTRATION PER PRESENTATION

Tablet Presentation	Suralan® Quattro® X-Mini	Suralan® Quattro® Mini	Suralan® Quattro® Small	Suralan® Quattro® Medium	Suralan® Quattro® Large	Suralan® Quattro® X-Large
Body Weight Range (kg)	1.25 - 2.5	>2.5 - 5	>5 - 10	>10 - 20	>20 - 40	>40 - 60
Sarolaner (mg)	5.00	10.00	20.00	40.00	80.00	120.00
Moxidectin (mg)	0.06	0.12	0.24	0.48	0.96	1.44
Pyrantel (mg)	12.50	25.00	50.00	100.00	200.00	300.00
Arpraziquantel (mg)	6.25	12.50	25.00	50.00	100.00	150.00

AVAILABLE IN 1 AND 4 TABLET PRESENTATIONS



For dogs from
1.25 to 2.5 kg

For dogs from
2.5 to 5 kg

For dog from
5 to 10 kg

For dogs from
10 to 20 kg

For dogs from
20 to 40 kg

For dogs from
40 to 60 kg

*Suralan® Quattro®: Protected innovation. Composition subject to pending international patent application N° PCT/PE2025/050033

A FORMULA
AS PURE
AS YOUR CARE

Suralan® Quattro®

It is a fundamental tool in preventive medicine, interrupting the transmission of clinically relevant diseases such as Babesiosis, Anaplasmosis, Ehrlichiosis, and Borreliosis. Likewise, it provides comprehensive protection against severe parasitic conditions, including the prevention of Dirofilaria (heartworm) and diseases caused by internal parasites (cestodes and nematodes).

Ectoparasites:

Immediate action (80 minutes average)² and persistent for 35 days against fleas (*Ctenocephalides felis*, *Ctenocephalides canis*), ticks (*Ixodes ricinus*, *I. hexagonus*, *Rhipicephalus sanguineus*, *Dermacentor reticulatus*, and *D. variabilis*, among others), and mites (*Demodex canis*, *Sarcoptes scabiei* var. *canis*, *Otodectes cynotis*).

Endoparasites:

Control of gastrointestinal nematodes (L4, L5, and adults: *Toxocara canis*, *Toxascaris leonina*, *Ancylostoma caninum*, *A. braziliense*, *Uncinaria stenocephala*, and *Trichuris vulpis*), lungworms (*Angiostrongylus vasorum*), heartworms (*Dirofilaria immitis*), and cestodes (*Dipylidium caninum*, *Taenia* spp., and *Echinococcus granulosus* / *E. multilocularis*).

ACTION AGAINST FLEAS

- At 8 hours post-administration, Suralan® Quattro® demonstrated 96% efficacy in eliminating the target flea population. This high efficacy remains constant, peaking at 99%¹ on day 28.
- Suralan® Quattro® represents a highly effective alternative for adulticidal flea treatment and control, delivering continuous protection for up to 5 weeks.
- The average onset of flea-killing activity for Suralan® Quattro® was clocked at 80 minutes².

ACTION AGAINST TICKS

- Within the first 8 hours post-administration, Suralan® Quattro® achieves 94% efficacy, which escalates to 98% within 24 hours³.
- Treatment with Suralan® Quattro® maintained optimal efficacy levels above 90% throughout the entire 5-week evaluation period, reaching 96% efficacy by day 35³.

ACTION AGAINST INTERNAL PARASITES



- By day 2, Suralan® Quattro® achieved 98% efficacy against nematodes, consistently sustaining protection above this threshold for 21 days⁴.
- Treatment with Suralan® Quattro® stands as a highly reliable therapeutic alternative for broad nematode control for up to 5 weeks⁴.

FIELD-PROVEN PROTECTION



Ask for it as

QUATTRO®

Available in
1 AND 4 SOFT CHEWS
presentation

www.suralan.com

BIBLIOGRAPHY

1.- Flores L, Krklec S, Aylas V, 2025. Effectiveness, tolerance, and residual efficacy of a soft chewable tablet based on sarolaner, moxidectin, pyrantel, and R-praziquantel for the treatment and control of fleas in naturally infested canines. 2.- Flores L, Krklec S, Aylas V, Ferrari E, 2025. Evaluation of the onset of pulicidal activity of a monthly oral formulation based on sarolaner, moxidectin, pyrantel, and R-praziquantel in naturally infested canines. 3.- Flores L, Krklec S, Aylas V, Ferrari E, 2025. Effectiveness, tolerance, and residual efficacy of a soft chewable tablet based on sarolaner, moxidectin, pyrantel, and R-praziquantel for the treatment and control of ticks in naturally infested canines. 4.- Flores L, Krklec S, Aylas V, Ferrari E, 2025. Effectiveness, tolerance, and residual efficacy of a soft chewable tablet based on sarolaner, moxidectin, pyrantel, and R-praziquantel for the treatment and control of nematodes in naturally infested canines.



Sample materials, packaging, whether digital or printed, are provided by Agroveter Market or its representatives for informational purposes only. The content is global and general in nature and shall not, under any circumstances, be construed as an attempt to undermine, infringe, or challenge the validity of any registration, patent, or intellectual property right in the country where this information is distributed or received.

SURALAN® QUATTRO® is a product of PETMEDICA®, the companion animal division of AGROVET MARKET S.A.

For more information about Suralan® Quattro® and its distribution network, visit: petmedica.vet

Av. Canadá 3798 - San Luis 15021. Lima - Perú

☎ 511 2 300 300 / (+51) 922 926 786 ✉ ventas@agrovetermarket.com

petmedica®



Find an authorized distributor